Hunan Nucien Pharmaceutical Co., Ltd. (SHA:688189)
China · Delayed Price · Currency is CNY 6.44
+0.03 (0.47%)
Sep 30, 2026, 4:00 PM EDT
SHA:688189 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,757 | 2,172 | 1,784 | 2,588 | 3,383 | 4,931 | |
Market Cap Growth | -43.97% | 21.75% | -31.04% | -23.51% | -31.39% | -27.96% |
Enterprise Value | 1,399 | 1,827 | 1,435 | 2,370 | 3,402 | 4,800 |
Last Close Price | 6.44 | 7.97 | 6.54 | 9.43 | 12.33 | 17.97 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 21.23 | 21.23 | 21.23 | 21.23 | 21.23 |
PS Ratio | 12.91 | 15.31 | 7.09 | 3.59 | 4.84 | 6.63 |
PB Ratio | 2.47 | 3.05 | 2.03 | 2.01 | 2.61 | 3.54 |
P/TBV Ratio | 2.52 | 3.13 | 2.25 | 2.22 | 2.90 | 4.04 |
P/FCF Ratio | - | 62.48 | - | 14.08 | - | - |
P/OCF Ratio | 84.72 | 18.96 | 1280.46 | 12.02 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 10.28 | 12.88 | 5.70 | 3.29 | 4.87 | 6.46 |
EV/EBITDA Ratio | - | - | - | 58.91 | - | - |
EV/EBIT Ratio | - | - | - | 546.78 | - | - |
EV/FCF Ratio | - | 52.55 | - | 12.90 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.09 | 0.01 | 0.25 | 0.25 | 0.42 | 0.34 |
Debt / EBITDA Ratio | - | - | - | 7.81 | - | - |
Debt / FCF Ratio | - | 0.29 | - | 1.77 | - | - |
Net Debt / Equity Ratio | -0.40 | -0.41 | -0.31 | -0.26 | -0.13 | -0.18 |
Net Debt / EBITDA Ratio | 4.56 | 4.40 | 0.87 | -8.48 | 5.16 | 1.42 |
Net Debt / FCF Ratio | 21.95 | -8.38 | 4.75 | -1.86 | 0.84 | 1.45 |
Asset Turnover | 0.14 | 0.14 | 0.17 | 0.39 | 0.34 | 0.35 |
Inventory Turnover | 2.55 | 2.16 | 2.83 | 4.24 | 2.67 | 1.80 |
Quick Ratio | 2.81 | 3.77 | 2.05 | 2.88 | 2.25 | 2.29 |
Current Ratio | 3.13 | 4.28 | 2.29 | 2.97 | 2.31 | 2.39 |
Return on Equity (ROE) | -19.01% | -18.83% | -35.61% | -0.84% | -7.26% | -12.11% |
Return on Assets (ROA) | -6.11% | -6.21% | -14.79% | 0.15% | -2.44% | -6.42% |
Return on Invested Capital (ROIC) | -22.15% | -19.65% | -44.86% | 0.42% | -7.03% | -20.22% |
Return on Capital Employed (ROCE) | -13.20% | -14.10% | -39.40% | 0.30% | -6.10% | -14.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -7.63% | -6.30% | -19.42% | -0.42% | -2.33% | -3.28% |
FCF Yield | -0.74% | 1.60% | -3.20% | 7.10% | -5.94% | -3.58% |
Buyback Yield / Dilution | 0.07% | -0.00% | 0.02% | -0.03% | 0.01% | -6.66% |
Total Shareholder Return | 0.07% | -0.00% | 0.02% | -0.03% | 0.01% | -6.66% |